- Home
- DEVS vs ICU Comparison
DEVS vs ICU Comparison
Compare DEVS & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEVS
- ICU
- Stock Information
- Founded
- DEVS N/A
- ICU 2018
- Country
- DEVS Canada
- ICU United States
- Employees
- DEVS N/A
- ICU N/A
- Industry
- DEVS
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- DEVS
- ICU Health Care
- Exchange
- DEVS NYSE
- ICU Nasdaq
- Market Cap
- DEVS 11.9M
- ICU 10.4M
- IPO Year
- DEVS N/A
- ICU N/A
- Fundamental
- Price
- DEVS $0.34
- ICU $0.61
- Analyst Decision
- DEVS
- ICU
- Analyst Count
- DEVS 0
- ICU 0
- Target Price
- DEVS N/A
- ICU N/A
- AVG Volume (30 Days)
- DEVS 524.3K
- ICU 19.2M
- Earning Date
- DEVS 07-22-2025
- ICU 08-12-2025
- Dividend Yield
- DEVS N/A
- ICU N/A
- EPS Growth
- DEVS N/A
- ICU N/A
- EPS
- DEVS N/A
- ICU N/A
- Revenue
- DEVS $10,164.00
- ICU $428,000.00
- Revenue This Year
- DEVS N/A
- ICU $754.07
- Revenue Next Year
- DEVS N/A
- ICU $100.09
- P/E Ratio
- DEVS N/A
- ICU N/A
- Revenue Growth
- DEVS N/A
- ICU N/A
- 52 Week Low
- DEVS $0.18
- ICU $0.31
- 52 Week High
- DEVS $3.00
- ICU $9.56
- Technical
- Relative Strength Index (RSI)
- DEVS N/A
- ICU 41.48
- Support Level
- DEVS N/A
- ICU $0.52
- Resistance Level
- DEVS N/A
- ICU $0.83
- Average True Range (ATR)
- DEVS 0.00
- ICU 0.16
- MACD
- DEVS 0.00
- ICU 0.04
- Stochastic Oscillator
- DEVS 0.00
- ICU 50.89
About DEVS DEVVSTREAM CORP
DevvStream Corp is a technology-based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve its sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.